IRIDEX Corporation — FY2012 Form 10-K
Reporting period: Fiscal year ended December 29, 2012 (52 weeks). The filing is an annual report; it does not provide a clear standalone FY2012 fourth-quarter financial summary. Financial results below distinguish continuing ophthalmology operations from discontinued aesthetics operations.
Business context and financial performance
IRIDEX develops, manufactures and sells ophthalmic laser systems, delivery devices and consumables used to treat serious eye diseases. In February 2012, it completed the sale of its aesthetics business to Cutera and presents that business as discontinued operations.
| Metric | FY2012 | FY2011 |
|---|---|---|
| Continuing revenue | $33.9 million | $33.2 million |
| Gross profit / gross margin | $16.3 million / 48.3% | $16.3 million / 49.1% |
| Operating income (loss) | $(0.9) million | $1.9 million |
| Continuing net income (loss) | $(0.2) million | $2.1 million |
| Net income, including discontinued operations | $1.4 million | $2.6 million |
| Cash from continuing operating activities | $(1.1) million | $2.3 million |
| Cash and cash equivalents at year-end | $11.9 million | $10.8 million |
| Debt at year-end | None | None |
| Working capital at year-end | $20.7 million | $20.6 million |
Recurring ophthalmology revenue rose 5.6% to $17.1 million. System revenue was broadly stable; OEM revenue declined 40% to $0.3 million as the associated product entered its end-of-life phase. International ophthalmology sales were $15.4 million, or 45.4% of continuing revenue. No customer represented 10% or more of revenue.
Material changes and unusual items
- Continuing revenue increased 2.1%, but continuing operations shifted from $2.1 million net income to a $0.2 million net loss. Operating expenses rose, including R&D (up 12.1% to $4.4 million), sales and marketing (up 5.9% to $7.9 million) and general and administrative expense (up 15.7% to $4.9 million). G&A included severance and related streamlining costs.
- Gross margin declined 0.8 percentage points, primarily due to increased manufacturing and service costs. Inventory increased to $8.0 million from $6.7 million; management said the investment was intended to support more consistent, efficient production.
- Continuing operating cash flow turned negative, with working-capital changes using cash, including a $1.4 million inventory increase. The overall cash balance nevertheless increased, principally reflecting cash flows from discontinued operations, including $4.6 million of investing cash flow associated with the business sale.
- FY2012 net income included $1.6 million of after-tax income from discontinued operations, including a $1.9 million after-tax gain on the sale. The aesthetics business itself reported a loss from discontinued operations for the year.
- IRIDEX recorded $0.8 million of income from the Synergetics patent settlement, the final annual installment. The company also recorded a $0.2 million expense from remeasurement of acquisition earn-out liabilities.
- The company repurchased approximately $2.8 million of common stock during FY2012, including a $2.0 million tender offer. A new one-year, $3.0 million repurchase program was approved in February 2013.
Liquidity, outlook and risks
Management stated that cash on hand and expected operating cash flows were sufficient for the next 12 months. Contractual operating-lease payments totaled $1.7 million, including $0.7 million due within one year. The filing provides no numerical revenue or earnings guidance; management described profitable growth as a goal. IRIDEX introduced the TxCell scanning laser delivery system late in 2012 and plans to pursue product development and recurring revenue growth.
Key risks include sustained losses or weak operating cash generation, competition and pricing pressure, uncertain adoption and regulatory clearance of new products, dependence on distributors and sole- or limited-source suppliers, and reimbursement or healthcare policy changes. International sales are significant and may be affected by a stronger U.S. dollar, economic conditions and local regulation. The filing also identifies a U.S. medical-device excise tax of 2.3% and warns that inability to pass it on could reduce profits. The aesthetics sale includes indemnification obligations; $0.5 million was held in escrow for potential claims.
After year-end, IRIDEX reported a $0.5 million insurance distribution and a March 2013 global distribution and supply agreement with Peregrine Surgical. IRIDEX committed to purchase $0.8 million of product annually over the agreement’s four-year term. The company had no off-balance-sheet arrangements and reported no pending litigation expected to materially affect operations or financial condition.
Important facts for investors to verify
- Whether ophthalmology can return to profitability and positive operating cash flow without the contribution of the sold aesthetics business.
- How much of future revenue and margin depends on recurring consumables, the Alcon arrangement and successful adoption of new products such as TxCell.
- Whether inventory growth converts to sales and whether manufacturing and service costs stabilize.
- The potential effects of the 2.3% medical-device tax, reimbursement changes, supplier concentration and foreign-exchange movements.
- The terms and potential dilution associated with 500,000 outstanding preferred shares, convertible into 1 million common shares under specified conditions, and the $5.0 million liquidation preference.
- Execution of the Peregrine purchase commitment, use of the new share-repurchase authorization, and resolution or release of the sale-related escrow.
The independent auditor issued an unmodified opinion on the financial statements. Management concluded disclosure controls and internal control over financial reporting were effective; the auditor did not attest to internal-control effectiveness.